ALX Oncology Holdings ALXO 深 滬
已收盤 09-05 16:00:00 美东时间
1.22
+0.140
+12.96%
華盛通- 最 高1.255
- 今 開1.05
- 成交量 82.78万股
- 最 低 1.0113
- 昨 收 1.08
- 總市值 6520.17万
- 52周最高 2.36
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.404
- 委 比 -46.80%
- 總股本 5344.40万
- 歷史最高 117.45
- 量 比 1.78
- 振 幅 22.56%
- 歷史最低 0.404
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ALX Oncology to Participate in Upcoming Investor Conferences in September
ALX Oncology's leadership will participate in two major conferences in September 2025: the Cantor Global Healthcare Conference featuring a fireside chat and one-on-one meetings on September 3, and the H.C. Wainwright Investment Conference focusing on one-on-one meetings on September 9. Both events will be held in New York. The webcast links and replay information are available on ALX Oncology’s website. The company, advancing novel cancer therapi...
08-29 16:00
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
ALX Oncology has initiated a Phase 1 clinical trial for its novel EGFR-targeted ADC, ALX2004, designed to treat EGFR-expressing solid tumors. The trial aims to evaluate safety and efficacy, with initial data expected in H1 2026. ALX2004 features an optimized antibody, linker, and payload to enhance therapeutic potential and reduce toxicity, building on promising preclinical results showing dose-dependent anti-tumor activity and a favorable safety...
08-19 12:00
ALX Oncology Appoints Dr. Curran to Board
An announcement from ALX Oncology Holdings ( ($ALXO) ) is now available. On Aug...
08-13 04:50
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology reported Q2 2025 financial results and corporate updates, highlighting advancements in their evorpacept and ALX2004 clinical programs. CD47 expression emerged as a key predictive biomarker for evorpacept response in HER2+ gastric cancer, with updated ASPEN-Breast trial design focusing on biomarker-driven strategies. The Phase 1 trial for ALX2004 remains on track, with first patient dosing expected in August. The company extended its ...
08-12 20:05
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
ALX Oncology Holdings's Earnings: A Preview
ALX Oncology Holdings (NASDAQ:ALXO) is set to give its latest quarterly earning...
08-12 02:03
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
ALX Oncology announces plans to report its Q2 2025 financial results on August 12, 2025, after market close, along with a business update. A teleconference and webcast will be held at 1:30pm PT / 4:30pm ET, accessible via phone or web. The event will include a live audio webcast with slides available on the Company's website. ALX Oncology is a clinical-stage biotech advancing novel cancer therapies, including evorpacept and ALX2004, with ongoing ...
08-05 12:00
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
ALX Oncology announced its participation in the Jefferies 2025 Global Healthcare Conference with a fireside chat scheduled for June 5, 2025, at 1:25 PM ET in New York. The webcast will be accessible via the company's website, and a replay will be available for 90 days. ALX Oncology focuses on developing innovative cancer therapies, including evorpacept and ALX2004, with ongoing clinical trials. More information is available on their website or Li...
05-30 12:00
